In one study, no significant bacterial infections were documented in all investigated patients over the age of 14 with IRAK4 deficiency. This may mean that in later stages of life, IRAK4 inhibition could provide benefits against certain diseases while maintaining immunity.
A study found that no bacterial infections occurred in all individuals aged 14 and older with IRAK4 deficiency. This finding suggests that inhibiting IRAK4 in later stages of life might provide therapeutic benefits for certain illnesses without compromising the immune system.